Distribution of HLA epitope frequencies in Turkish population

Objectives: The antibodies interact with the “Human Leukocyte Antigen (HLA) antigens” at specific epitopes. “Epitopes” are present on a single HLA or shared by multiple antigens. In this study, we aim to determine the frequency of prevalent epitopes common in the Turkish population. ethods: Non-related 644 healthy volunteers were recruited, and The “HLA-A, -B, -C, -DR -DQ’s” were typed using the “Next Generation Sequencing”. The provisional and confirmed epitopes were identified using the “HLA Epitope Registry databases, HLA Epitopia Maps and Immucor Epitope databases” dated 07.02.2018. Epitope frequencies were calculated by counting the shared epi- topes in the total number of shared HLA Class epitopes in our sample database. Results: Class I HLA’s had 298 epitopes that repeated a total of 158,117 times with frequencies ranging between 0.0006 and 2.03%, and the most frequent epitope was 170RY found on 119 different alleles. Class II HLA’s had 193 epitopes that repeated a total of 93,082 times with fre- quencies ranging between 0.002 and 1.36%, and the most frequent epitope was 108P found on 42 different alleles. Conclusions: Our findings summarize both the provi- sional, and confirmed epitope frequencies in the Turkish population and may help clinicians and immunogeneticists develop a better understanding of HLA epitope mismatches.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Thorsby E. A short history of HLA. Tissue Antigens 2009;74: 101–16.
Beck S, Geraghty D, Inoko H, Rowen L, Aguado B, Bahram S, et al. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999;401:921–3.
Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev 2009;22:370–85.
Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol 2005;14:175–82.
Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 2009;54:15–39.
Claas FH, Duquesnoy RJ. The polymorphic alloimmune response in clinical transplantation. Curr Opin Immunol 2008;20:566–7.
Alfirevic A, Pirmohamed M. Drug induced hypersensitivity and the HLA complex. Pharmaceuticals 2010;4:69–90.
Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012;92: 757–65.
Kramer C, Heidt S, Claas FHJ. Towards the identification of the relative immunogenicity of individual HLA antibody epitopes. Hum Immunol 2019;80:218–20.
Claas FHJ, Dankers MK, Oudshoorn M, van Rood JJ, Mulder A, Roelen DL, et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 2005;14:187–91.
Doxiadis II, Duquesnoy RJ, Claas FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005;17:536–40. 12. Walton DC, Hiho SJ, Cantwell LS, Diviney MB, Wright ST, Snell GI, et al. HLA matching at the eplet level protects against chronic lung allograft dysfunction. Am J Transplant 2016;16:2695–703.
Goodman RS, Taylor CJ, O’Rourke CM, Lynch A, Bradley JA, Key T. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation 2006;81:1331–6.
Kosmoliaptsis V, Bradley JA, Sharples LD, Chaudhry A, Key T, Goodman RS, et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008; 85:1817–25.
Duquesnoy RJ, Awadalla Y, Lomago J, Jelinek L, Howe J, Zern D, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol 2008;18:352–60.
Kosmoliaptsis V, Chaudhry AN, Sharples LD, Halsall DJ, Dafforn TR, Bradley JA, et al. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2009; 88:791–8.
Duquesnoy RJ, Marrari M. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transpl Immunol 2011;24:164–71.
Hönger G, Fornaro I, Granado C, Tiercy J-M, Hösli I, Schaub S. Frequency and determinants of pregnancy-induced child-specific sensitization. Am J Transplant 2013;13:746–53.
Wiebe C, Nickerson P. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013;18: 470–7.
Wiebe C, Nevins TE, Robiner WN, Thomas W, Matas AJ, Nickerson PW. The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant 2015;15:2197–202.
Filippone EJ, Farber JL. Humoral immunity in renal transplantation: epitopes, Cw and DP, and complement-activating capability - an update. Clin Transplant 2015;29:279–87.
Sapir-Pichhadze R, Tinckam K, Quach K, Logan AG, Laupacis A, John R, et al. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant 2015;15:137–48.
Singh P, Filippone EJ, Colombe BW, Shah AP, Zhan T, Harach M, et al. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized. Clin Transplant 2016;30:71–80.
Sullivan PM, Warner P, Kemna MS, Albers EL, Law SP, Weiss NS, et al. HLA molecular epitope mismatching and long-term graft loss in pediatric heart transplant recipients. J Heart Lung Transplant 2015;34:950–7.
Duquesnoy RJ. HLA epitopes and tolerance induction protocols. Am J Transplant 2014;14:2667.
Tambur AR. HLA-epitope matching or eplet risk stratification: the devil is in the details. Front Immunol 2018;9:2010.
Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21: 1398–406.
Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12:1157–67.
Lucas DP, Leffell MS, Zachary AA. Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response. Transplantation 2015;99:77–85.
El-Awar N, Jucaud V, Nguyen A. HLA epitopes: the targets of monoclonal and alloantibodies defined. J Immunol Res 2017; 2017:1–16.
Tafulo S, Malheiro J, Santos S, Dias L, Almeida M, Martins S, et al. Degree of HLA class II eplet mismatch load improves prediction of antibody-mediated rejection in living donor kidney transplantation. Hum Immunol 2019;80:966–75.
Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, et al. Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol 2017;28:3353–62.
Duquesnoy RJ, Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 2002;63: 353–63.
Otten HG, Calis JJA, Keşmir C, van Zuilen AD, Spierings E. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation. Hum Immunol 2013;74:290–6.
DuquesnoyRJ.Humanleukocyteantigenepitopeantigenicityand immunogenicity. Curr Opin Organ Transplant 2014;19:428–35.
Ekong UD, Antala S, Bow L, Sese D, Morotti R, Rodriguez-Davalos M, et al. HLA, non-HLA antibodies, and eplet mismatches in pediatric liver transplantation: observations from a small, single-center cohort. Exp Clin Transplant 2019; 1:6–17.
Uyar FA, Dorak MT, Saruhan-Direkeneli G. Human leukocyte antigen-A, -B and -C alleles and human leukocyte antigen haplotypes in Turkey: relationship to other populations. Tissue Antigens 2004;64:180–7.
Kaya Z,Gönen S,Caliskan B,Kemer Z,Ünal AB,Değirmenci E. HLA genotypes inTurkish hemato poietic cell recipients and likelihood of finding a matched donor through family searches. Exp Clin Transplant 2017;17:813–8.
Chen JJ, Hollenbach JA, Trachtenberg EA, Just JJ, Carrington M, Rønningen KS, et al. Hardy-Weinberg testing for HLA class II (DRB1, DQA1, DQB1, and DPB1) loci in 26 human ethnic groups. Tissue Antigens 1999;54:533–42.

APA	Oguz R, SAVRAN OGUZ F, ogret y, SENTÜRK ÇIFTÇI H, Karataş Ş, KIVANC D, Karadeniz S, Aydin F (2022). Distribution of HLA epitope frequencies in Turkish population. , 52 - 58. 10.1515/tjb-2021-0083
Chicago	Oguz Rustu,SAVRAN OGUZ FATMA,ogret yeliz,SENTÜRK ÇIFTÇI HAYRIYE,Karataş Şule,KIVANC DEMET,Karadeniz Sedat,Aydin Filiz Distribution of HLA epitope frequencies in Turkish population. (2022): 52 - 58. 10.1515/tjb-2021-0083
MLA	Oguz Rustu,SAVRAN OGUZ FATMA,ogret yeliz,SENTÜRK ÇIFTÇI HAYRIYE,Karataş Şule,KIVANC DEMET,Karadeniz Sedat,Aydin Filiz Distribution of HLA epitope frequencies in Turkish population. , 2022, ss.52 - 58. 10.1515/tjb-2021-0083
AMA	Oguz R,SAVRAN OGUZ F,ogret y,SENTÜRK ÇIFTÇI H,Karataş Ş,KIVANC D,Karadeniz S,Aydin F Distribution of HLA epitope frequencies in Turkish population. . 2022; 52 - 58. 10.1515/tjb-2021-0083
Vancouver	Oguz R,SAVRAN OGUZ F,ogret y,SENTÜRK ÇIFTÇI H,Karataş Ş,KIVANC D,Karadeniz S,Aydin F Distribution of HLA epitope frequencies in Turkish population. . 2022; 52 - 58. 10.1515/tjb-2021-0083
IEEE	Oguz R,SAVRAN OGUZ F,ogret y,SENTÜRK ÇIFTÇI H,Karataş Ş,KIVANC D,Karadeniz S,Aydin F "Distribution of HLA epitope frequencies in Turkish population." , ss.52 - 58, 2022. 10.1515/tjb-2021-0083
ISNAD	Oguz, Rustu vd. "Distribution of HLA epitope frequencies in Turkish population". (2022), 52-58. https://doi.org/10.1515/tjb-2021-0083

APA	Oguz R, SAVRAN OGUZ F, ogret y, SENTÜRK ÇIFTÇI H, Karataş Ş, KIVANC D, Karadeniz S, Aydin F (2022). Distribution of HLA epitope frequencies in Turkish population. Türk Biyokimya Dergisi, 47(3), 52 - 58. 10.1515/tjb-2021-0083
Chicago	Oguz Rustu,SAVRAN OGUZ FATMA,ogret yeliz,SENTÜRK ÇIFTÇI HAYRIYE,Karataş Şule,KIVANC DEMET,Karadeniz Sedat,Aydin Filiz Distribution of HLA epitope frequencies in Turkish population. Türk Biyokimya Dergisi 47, no.3 (2022): 52 - 58. 10.1515/tjb-2021-0083
MLA	Oguz Rustu,SAVRAN OGUZ FATMA,ogret yeliz,SENTÜRK ÇIFTÇI HAYRIYE,Karataş Şule,KIVANC DEMET,Karadeniz Sedat,Aydin Filiz Distribution of HLA epitope frequencies in Turkish population. Türk Biyokimya Dergisi, vol.47, no.3, 2022, ss.52 - 58. 10.1515/tjb-2021-0083
AMA	Oguz R,SAVRAN OGUZ F,ogret y,SENTÜRK ÇIFTÇI H,Karataş Ş,KIVANC D,Karadeniz S,Aydin F Distribution of HLA epitope frequencies in Turkish population. Türk Biyokimya Dergisi. 2022; 47(3): 52 - 58. 10.1515/tjb-2021-0083
Vancouver	Oguz R,SAVRAN OGUZ F,ogret y,SENTÜRK ÇIFTÇI H,Karataş Ş,KIVANC D,Karadeniz S,Aydin F Distribution of HLA epitope frequencies in Turkish population. Türk Biyokimya Dergisi. 2022; 47(3): 52 - 58. 10.1515/tjb-2021-0083
IEEE	Oguz R,SAVRAN OGUZ F,ogret y,SENTÜRK ÇIFTÇI H,Karataş Ş,KIVANC D,Karadeniz S,Aydin F "Distribution of HLA epitope frequencies in Turkish population." Türk Biyokimya Dergisi, 47, ss.52 - 58, 2022. 10.1515/tjb-2021-0083
ISNAD	Oguz, Rustu vd. "Distribution of HLA epitope frequencies in Turkish population". Türk Biyokimya Dergisi 47/3 (2022), 52-58. https://doi.org/10.1515/tjb-2021-0083